Antisense Inhibition of Hypertension in the Spontaneously Hypertensive Rat
Phosphorothioated antisense oligodeoxynucleotide (ASODN) targeted to angiotensinogen mRNA was administered intracerebroventricularly in spontaneously hypertensive rats to test whether angiotensinogen reduction would lower their hypertensive blood pressures. The ASODN lowers hypertensive blood pressu...
Gespeichert in:
Veröffentlicht in: | Hypertension (Dallas, Tex. 1979) Tex. 1979), 1995-03, Vol.25 (3), p.314-319 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 319 |
---|---|
container_issue | 3 |
container_start_page | 314 |
container_title | Hypertension (Dallas, Tex. 1979) |
container_volume | 25 |
creator | Wielbo, Donna Sernia, Conrad Gyurko, Robert Phillips, M. Ian |
description | Phosphorothioated antisense oligodeoxynucleotide (ASODN) targeted to angiotensinogen mRNA was administered intracerebroventricularly in spontaneously hypertensive rats to test whether angiotensinogen reduction would lower their hypertensive blood pressures. The ASODN lowers hypertensive blood pressures to normotensive levels in spontaneously hypertensive rats; sense oligodeoxynucleotide had no effect. Administration of phosphorothioated ASODN produced a prolonged duration of lowered blood pressure. Injections of ASODN at the same dose that decreased hypertension when administered centrally did not result in blood pressure decreases when administered intra-arterially. Furthermore, angiotensinogen production was decreased in the brain stem and significantly decreased in the hypothalamus of the ASODN-treated rats (P < .05), supporting the concept of centrally mediated regulation of hypertension by an overactive brain angiotensin system. To determine the distribution of centrally administered oligodeoxynucleotides, fluorescein isothiocyanate-conjugated oligodeoxynucleotides were injected directly into the lateral ventricles. One hour later, oligodeoxynucleotides were distributed throughout the lateral and third ventricles, with tissue and cellular uptake observed in discrete cells at the injection site. This indicates that the oligodeoxynucleotides are taken up rapidly by brain cells and that they permeate the areas surrounding brain nuclei involved in central blood pressure regulation and volume homeostasis. The results confirm and extend our previous study with phosphodiester ASODN and show that phosphorothioation modification increases the duration of the response and is taken up in vivo. We conclude that with modification, ASODN inhibition of angiotensinogen mRNA translation can be used for a prolonged, profound decrease in mean arterial pressure in the spontaneously hypertensive rat through a central mechanism. (Hypertension. 1995;25:314-319.) |
doi_str_mv | 10.1161/01.HYP.25.3.314 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77160134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14746970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4343-ce27ff92c2d09570171ba9b7dfeeeafcc03620ab0ee4f5a9b26299d37237b00b3</originalsourceid><addsrcrecordid>eNpdkU2LFDEQhoMo6zh69iQ0It66tyofnclxWdRZWVD8AD2FdE-F6bUnPSZpl_n3ZphhEXMpqt4nVcVbjL1EaBBbvARs1j8_N1w1ohEoH7EFKi5rqVrxmC0AjawN4o-n7FlKdwAopdQX7EKvtNJKLdjHq5CHRCFRdRO2QzfkYQrV5Kv1YU8xF-GYD6HKW6q-7qeQXaBpTuPhH-IPVV9cfs6eeDcmenGOS_b9_btv1-v69tOHm-ur27qXQoq6J669N7znGzBKA2rsnOn0xhOR830PouXgOiCSXhWFt9yYjdBc6A6gE0v29tR3H6ffM6Vsd0PqaRxPm1mtsQUso5bs9X_g3TTHUHazHBRvW66hQJcnqI9TSpG83cdh5-LBItijxRbQFostV1bYYnH58ercdu52tHngz54W_c1Zd6l3o48u9EN6wEQ5wUodB8sTdj-NmWL6Nc73FO2W3Ji3FsqTvF3VaEyBS1YfS0L8BVVdk2M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>205266270</pqid></control><display><type>article</type><title>Antisense Inhibition of Hypertension in the Spontaneously Hypertensive Rat</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Wielbo, Donna ; Sernia, Conrad ; Gyurko, Robert ; Phillips, M. Ian</creator><creatorcontrib>Wielbo, Donna ; Sernia, Conrad ; Gyurko, Robert ; Phillips, M. Ian</creatorcontrib><description>Phosphorothioated antisense oligodeoxynucleotide (ASODN) targeted to angiotensinogen mRNA was administered intracerebroventricularly in spontaneously hypertensive rats to test whether angiotensinogen reduction would lower their hypertensive blood pressures. The ASODN lowers hypertensive blood pressures to normotensive levels in spontaneously hypertensive rats; sense oligodeoxynucleotide had no effect. Administration of phosphorothioated ASODN produced a prolonged duration of lowered blood pressure. Injections of ASODN at the same dose that decreased hypertension when administered centrally did not result in blood pressure decreases when administered intra-arterially. Furthermore, angiotensinogen production was decreased in the brain stem and significantly decreased in the hypothalamus of the ASODN-treated rats (P < .05), supporting the concept of centrally mediated regulation of hypertension by an overactive brain angiotensin system. To determine the distribution of centrally administered oligodeoxynucleotides, fluorescein isothiocyanate-conjugated oligodeoxynucleotides were injected directly into the lateral ventricles. One hour later, oligodeoxynucleotides were distributed throughout the lateral and third ventricles, with tissue and cellular uptake observed in discrete cells at the injection site. This indicates that the oligodeoxynucleotides are taken up rapidly by brain cells and that they permeate the areas surrounding brain nuclei involved in central blood pressure regulation and volume homeostasis. The results confirm and extend our previous study with phosphodiester ASODN and show that phosphorothioation modification increases the duration of the response and is taken up in vivo. We conclude that with modification, ASODN inhibition of angiotensinogen mRNA translation can be used for a prolonged, profound decrease in mean arterial pressure in the spontaneously hypertensive rat through a central mechanism. (Hypertension. 1995;25:314-319.)</description><identifier>ISSN: 0194-911X</identifier><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/01.HYP.25.3.314</identifier><identifier>PMID: 7875755</identifier><identifier>CODEN: HPRTDN</identifier><language>eng</language><publisher>Philadelphia, PA: American Heart Association, Inc</publisher><subject>Angiotensinogen - biosynthesis ; Angiotensinogen - genetics ; Animals ; Antisense Elements (Genetics) - genetics ; Arterial hypertension. Arterial hypotension ; Base Sequence ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Pressure - drug effects ; Brain - physiology ; Cardiology. Vascular system ; Experimental diseases ; Fluorescein-5-isothiocyanate ; Hypertension - genetics ; Hypertension - prevention & control ; Injections, Intraventricular ; Male ; Medical sciences ; Molecular Sequence Data ; Oligonucleotides, Antisense - pharmacology ; Rats ; Rats, Inbred SHR ; RNA, Messenger - genetics</subject><ispartof>Hypertension (Dallas, Tex. 1979), 1995-03, Vol.25 (3), p.314-319</ispartof><rights>1995 American Heart Association, Inc.</rights><rights>1995 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Mar 1995</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4343-ce27ff92c2d09570171ba9b7dfeeeafcc03620ab0ee4f5a9b26299d37237b00b3</citedby><cites>FETCH-LOGICAL-c4343-ce27ff92c2d09570171ba9b7dfeeeafcc03620ab0ee4f5a9b26299d37237b00b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,3674,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3444850$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7875755$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wielbo, Donna</creatorcontrib><creatorcontrib>Sernia, Conrad</creatorcontrib><creatorcontrib>Gyurko, Robert</creatorcontrib><creatorcontrib>Phillips, M. Ian</creatorcontrib><title>Antisense Inhibition of Hypertension in the Spontaneously Hypertensive Rat</title><title>Hypertension (Dallas, Tex. 1979)</title><addtitle>Hypertension</addtitle><description>Phosphorothioated antisense oligodeoxynucleotide (ASODN) targeted to angiotensinogen mRNA was administered intracerebroventricularly in spontaneously hypertensive rats to test whether angiotensinogen reduction would lower their hypertensive blood pressures. The ASODN lowers hypertensive blood pressures to normotensive levels in spontaneously hypertensive rats; sense oligodeoxynucleotide had no effect. Administration of phosphorothioated ASODN produced a prolonged duration of lowered blood pressure. Injections of ASODN at the same dose that decreased hypertension when administered centrally did not result in blood pressure decreases when administered intra-arterially. Furthermore, angiotensinogen production was decreased in the brain stem and significantly decreased in the hypothalamus of the ASODN-treated rats (P < .05), supporting the concept of centrally mediated regulation of hypertension by an overactive brain angiotensin system. To determine the distribution of centrally administered oligodeoxynucleotides, fluorescein isothiocyanate-conjugated oligodeoxynucleotides were injected directly into the lateral ventricles. One hour later, oligodeoxynucleotides were distributed throughout the lateral and third ventricles, with tissue and cellular uptake observed in discrete cells at the injection site. This indicates that the oligodeoxynucleotides are taken up rapidly by brain cells and that they permeate the areas surrounding brain nuclei involved in central blood pressure regulation and volume homeostasis. The results confirm and extend our previous study with phosphodiester ASODN and show that phosphorothioation modification increases the duration of the response and is taken up in vivo. We conclude that with modification, ASODN inhibition of angiotensinogen mRNA translation can be used for a prolonged, profound decrease in mean arterial pressure in the spontaneously hypertensive rat through a central mechanism. (Hypertension. 1995;25:314-319.)</description><subject>Angiotensinogen - biosynthesis</subject><subject>Angiotensinogen - genetics</subject><subject>Animals</subject><subject>Antisense Elements (Genetics) - genetics</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Base Sequence</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood Pressure - drug effects</subject><subject>Brain - physiology</subject><subject>Cardiology. Vascular system</subject><subject>Experimental diseases</subject><subject>Fluorescein-5-isothiocyanate</subject><subject>Hypertension - genetics</subject><subject>Hypertension - prevention & control</subject><subject>Injections, Intraventricular</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molecular Sequence Data</subject><subject>Oligonucleotides, Antisense - pharmacology</subject><subject>Rats</subject><subject>Rats, Inbred SHR</subject><subject>RNA, Messenger - genetics</subject><issn>0194-911X</issn><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU2LFDEQhoMo6zh69iQ0It66tyofnclxWdRZWVD8AD2FdE-F6bUnPSZpl_n3ZphhEXMpqt4nVcVbjL1EaBBbvARs1j8_N1w1ohEoH7EFKi5rqVrxmC0AjawN4o-n7FlKdwAopdQX7EKvtNJKLdjHq5CHRCFRdRO2QzfkYQrV5Kv1YU8xF-GYD6HKW6q-7qeQXaBpTuPhH-IPVV9cfs6eeDcmenGOS_b9_btv1-v69tOHm-ur27qXQoq6J669N7znGzBKA2rsnOn0xhOR830PouXgOiCSXhWFt9yYjdBc6A6gE0v29tR3H6ffM6Vsd0PqaRxPm1mtsQUso5bs9X_g3TTHUHazHBRvW66hQJcnqI9TSpG83cdh5-LBItijxRbQFostV1bYYnH58ercdu52tHngz54W_c1Zd6l3o48u9EN6wEQ5wUodB8sTdj-NmWL6Nc73FO2W3Ji3FsqTvF3VaEyBS1YfS0L8BVVdk2M</recordid><startdate>199503</startdate><enddate>199503</enddate><creator>Wielbo, Donna</creator><creator>Sernia, Conrad</creator><creator>Gyurko, Robert</creator><creator>Phillips, M. Ian</creator><general>American Heart Association, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>199503</creationdate><title>Antisense Inhibition of Hypertension in the Spontaneously Hypertensive Rat</title><author>Wielbo, Donna ; Sernia, Conrad ; Gyurko, Robert ; Phillips, M. Ian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4343-ce27ff92c2d09570171ba9b7dfeeeafcc03620ab0ee4f5a9b26299d37237b00b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Angiotensinogen - biosynthesis</topic><topic>Angiotensinogen - genetics</topic><topic>Animals</topic><topic>Antisense Elements (Genetics) - genetics</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Base Sequence</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood Pressure - drug effects</topic><topic>Brain - physiology</topic><topic>Cardiology. Vascular system</topic><topic>Experimental diseases</topic><topic>Fluorescein-5-isothiocyanate</topic><topic>Hypertension - genetics</topic><topic>Hypertension - prevention & control</topic><topic>Injections, Intraventricular</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molecular Sequence Data</topic><topic>Oligonucleotides, Antisense - pharmacology</topic><topic>Rats</topic><topic>Rats, Inbred SHR</topic><topic>RNA, Messenger - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wielbo, Donna</creatorcontrib><creatorcontrib>Sernia, Conrad</creatorcontrib><creatorcontrib>Gyurko, Robert</creatorcontrib><creatorcontrib>Phillips, M. Ian</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wielbo, Donna</au><au>Sernia, Conrad</au><au>Gyurko, Robert</au><au>Phillips, M. Ian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antisense Inhibition of Hypertension in the Spontaneously Hypertensive Rat</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><addtitle>Hypertension</addtitle><date>1995-03</date><risdate>1995</risdate><volume>25</volume><issue>3</issue><spage>314</spage><epage>319</epage><pages>314-319</pages><issn>0194-911X</issn><eissn>1524-4563</eissn><coden>HPRTDN</coden><abstract>Phosphorothioated antisense oligodeoxynucleotide (ASODN) targeted to angiotensinogen mRNA was administered intracerebroventricularly in spontaneously hypertensive rats to test whether angiotensinogen reduction would lower their hypertensive blood pressures. The ASODN lowers hypertensive blood pressures to normotensive levels in spontaneously hypertensive rats; sense oligodeoxynucleotide had no effect. Administration of phosphorothioated ASODN produced a prolonged duration of lowered blood pressure. Injections of ASODN at the same dose that decreased hypertension when administered centrally did not result in blood pressure decreases when administered intra-arterially. Furthermore, angiotensinogen production was decreased in the brain stem and significantly decreased in the hypothalamus of the ASODN-treated rats (P < .05), supporting the concept of centrally mediated regulation of hypertension by an overactive brain angiotensin system. To determine the distribution of centrally administered oligodeoxynucleotides, fluorescein isothiocyanate-conjugated oligodeoxynucleotides were injected directly into the lateral ventricles. One hour later, oligodeoxynucleotides were distributed throughout the lateral and third ventricles, with tissue and cellular uptake observed in discrete cells at the injection site. This indicates that the oligodeoxynucleotides are taken up rapidly by brain cells and that they permeate the areas surrounding brain nuclei involved in central blood pressure regulation and volume homeostasis. The results confirm and extend our previous study with phosphodiester ASODN and show that phosphorothioation modification increases the duration of the response and is taken up in vivo. We conclude that with modification, ASODN inhibition of angiotensinogen mRNA translation can be used for a prolonged, profound decrease in mean arterial pressure in the spontaneously hypertensive rat through a central mechanism. (Hypertension. 1995;25:314-319.)</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>7875755</pmid><doi>10.1161/01.HYP.25.3.314</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0194-911X |
ispartof | Hypertension (Dallas, Tex. 1979), 1995-03, Vol.25 (3), p.314-319 |
issn | 0194-911X 1524-4563 |
language | eng |
recordid | cdi_proquest_miscellaneous_77160134 |
source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
subjects | Angiotensinogen - biosynthesis Angiotensinogen - genetics Animals Antisense Elements (Genetics) - genetics Arterial hypertension. Arterial hypotension Base Sequence Biological and medical sciences Blood and lymphatic vessels Blood Pressure - drug effects Brain - physiology Cardiology. Vascular system Experimental diseases Fluorescein-5-isothiocyanate Hypertension - genetics Hypertension - prevention & control Injections, Intraventricular Male Medical sciences Molecular Sequence Data Oligonucleotides, Antisense - pharmacology Rats Rats, Inbred SHR RNA, Messenger - genetics |
title | Antisense Inhibition of Hypertension in the Spontaneously Hypertensive Rat |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A57%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antisense%20Inhibition%20of%20Hypertension%20in%20the%20Spontaneously%20Hypertensive%20Rat&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Wielbo,%20Donna&rft.date=1995-03&rft.volume=25&rft.issue=3&rft.spage=314&rft.epage=319&rft.pages=314-319&rft.issn=0194-911X&rft.eissn=1524-4563&rft.coden=HPRTDN&rft_id=info:doi/10.1161/01.HYP.25.3.314&rft_dat=%3Cproquest_cross%3E14746970%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=205266270&rft_id=info:pmid/7875755&rfr_iscdi=true |